SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortClinical Trial Published on 2023-02-012023-07-10 Journal: Hematological oncology [Category] COVID19(2023년), [키워드] BTK inhibitors chronic lymphocytic leukemia COVID-19 outcome SARS-CoV-2 [DOI] 10.1002/hon.3092 PMC 바로가기 [Article Type] Clinical Trial
Updates and advances in multiple sclerosis neurotherapeuticsarticle Published on 2022-10-312024-09-02 Journal: Neurodegenerative Disease Management [Category] 대상포진, [키워드] autologous hematopoietic stem cell transplantation BTK inhibitors Disease-modifying therapy early highly effective therapy escalation therapy multiple sclerosis neuroprotective agents Progressive multiple sclerosis relapsing multiple sclerosis remyelinating therapies [DOI] 10.2217/nmt-2021-0058 PMC 바로가기 [Article Type] article
Chronic Lymphocytic Leukemia in the SARS-CoV-2 PandemicSARS-CoV-2 유행병의 만성 림프구성 백혈병Review Published on 2022-02-012022-09-12 Journal: Current oncology reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antagonists anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses antibody BTK BTK inhibitors cancers Case fatality rate caused CFR CFRs chronic chronic lymphocytic leukemia Clinical course CLL CLL patient CLL patients Comorbidity contribute controls COVID-19 COVID-19 incidence COVID-19 vaccine decrease deficiency Efficacy elevated form General population greater healthy Hospitalization immune immune response immune system Immunosuppression IMPROVE incidence Infection leukemia lymphoproliferative disease malignancies malignancy monoclonal antibodies older patients outbreak outcome Oxygen therapy pandemic Patient patients with comorbidity Prevalence recent reduced reported response risk of death SARS-CoV-2 SARS-CoV-2 positivity severe infections significantly significantly higher Spike-specific antibody the disease the median the SARS-CoV-2 therapy Treatment vaccination Vaccine Vaccines [DOI] 10.1007/s11912-022-01198-z PMC 바로가기 [Article Type] Review
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A reviewResearch article Published on 2021-09-012022-10-05 Journal: Metabolism Open [Category] 신약개발, [키워드] a BTK inhibitor Acalabrutinib Activation affected B cell Bruton tyrosine kinase inhibitors BTK BTK inhibitor BTK inhibitors Cancer caused clinical study Coronavirus disease 2019 COVID-19 COVID-19 infected patients database drug Elsevier English Evidence Google Scholar Host Ibrutinib include Inflammation inhibition inhibitor Lung injury Macrophage management pandemic Pathways Patient potential therapeutic agent protective effect pulmonary injury regulate searched severe COVID-19 shown Signaling small molecule survival therapeutic strategy Treatment tyrosine tyrosine kinase inhibitor Web of Science Wuhan, China [DOI] 10.1016/j.metop.2021.100116 [Article Type] Research article
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia만성 림프구 백혈병 환자에서 제 1 및 제 2 코비드 -19 백신 접종 후 항체 반응Clinical Trial Published on 2021-07-302022-08-09 Journal: Blood Cancer Journal [Category] 임상, 진단, [키워드] Adaptive immunity Antibody Response Antibody responses Antibody titre antibody titres B-cell blood sample Blood samples BNT162b2 BNT162b2 mRNA vaccine booster vaccines BTK inhibitor BTK inhibitors ChAdOx1 Chronic lymphocytic leukaemia clinical risk CLL COVID-19 vaccines detectable dried blood spot Dried blood spots extended interval failure Filter Paper generate healthy donor healthy donors IgA deficiency Immunosuppression Multivariate analysis offer Patient profile remained SARS-COV-2 infection second vaccination Severe infection spike-specific antibody response Spike-specific antibody responses Support the antibody response the patient titre titres Translational research Treatment utility vaccination Vaccination strategy Vaccine venepuncture [DOI] 10.1038/s41408-021-00528-x PMC 바로가기 [Article Type] Clinical Trial
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery PerspectiveReview Published on 2021-07-162022-10-29 Journal: International Journal of Molecular Sciences [Category] Coronavirus, SARS, [키워드] approval Bioavailability Bruton’s kinase BTK inhibitors cancer treatment Chemistry chronic inflammation clinical trial Compound condition delivery drug drug delivery hematological cancer Ibrutinib inhibitor kinase leukemia limitations lymphomas malignancies overcome reported SARS-COV-2 infection Treatment tyrosine [DOI] 10.3390/ijms22147641 PMC 바로가기 [Article Type] Review
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effectsarticle Published on 2021-07-012024-09-02 Journal: Frontiers in immunology [Category] 대상포진, [키워드] BTK inhibitors Ibrutinib immune cells infections leukemia off-target effects vaccination [DOI] 10.3389/fimmu.2021.686768 PMC 바로가기 [Article Type] article
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19Article Published on 2021-06-302022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS, [키워드] ACE2 acute respiratory syndrome binding energy BTK BTK inhibitor BTK inhibitors carried caused clinical trial complexes computational studies conducted coronavirus COVID-19 COVID-19 patient disease docking drug Dyspnea Health Host hypercoagulability hypoxia Ibrutinib IMPROVE inhibitor inhibitors of SARS-CoV-2 inositol 1,3,4,5-tetrakisphosphate MD simulations mechanism mechanism of action molecular nonstructural protein Oxygenation Pathogenesis Potential protein-ligand binding free energy recent reduce Replication reported Result SARS-CoV-2 screened Screening selected spebrutinib target Thromboinflammation TMPRSS2 treat tyrosine viral entry Virtual screening zanubrutinib [DOI] 10.3390/ijms22137071 PMC 바로가기 [Article Type] Article
Differential impact of BTK active site inhibitors on the conformational state of full-length BTKResearch Article Published on 2020-11-232022-10-31 Journal: eLife [Category] Coronavirus, SARS, [키워드] activated Affect allergy Allostery antibodies approved Asthma B cell B-cell B-cells bind binding Blood bruton tyrosine kinase BTK BTK inhibitor BTK inhibitors Cancer Cancer cells cancers catalytic activity change Chemotherapy conformational consequence COVID-19 Diseases disorder disrupt disrupting domain domains drug drug resistance drugs Effect effective enzyme examined FIVE full-length full-length protein Future help hydrogen/deuterium exchange mass spectrometry Ibrutinib inactive increase inhibitor inhibitors Interaction Joseph Kinase inhibitor leukemia lymphoma lymphomas maintain mechanism modify Mutation None not affect nuclear magnetic resonance other compound other disease phosphate Previous effort Protein Proteins Region regions Regulatory regulatory domain regulatory region Research responsible shifting treat treated treating COVID-19 Treatment treatment strategy tyrosine understanding while White blood cell [DOI] 10.7554/eLife.60470 PMC 바로가기 [Article Type] Research Article
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus Research Published on 2020-07-092022-10-05 Journal: Leukemia [Category] SARS, 치료법, [키워드] Admission advanced age age appear BTK inhibitors Campus characterized chronic lymphocytic leukemia CLL Comorbidity Course COVID-19 COVID-19 in patient COVID-19 severity diagnosed disease European identify immunodeficiency increase initiative intensive care International joint Mild Mortality multicenter Odds ratio outcome oxygen Patient predictor Protective receiving regimen retrospective severe complication severe COVID-19 severe disease susceptible Treatment with mild disease [DOI] 10.1038/s41375-020-0959-x [Article Type] Research